EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial methotrexate therapy fails.

From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in rheumatology care.

According to a EULAR press release, the data “suggest the potential for CAR T-cell therapy and other B-cell depleting therapies to reset the immune system in multiple RMD, allowing patients to ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed ...

EULAR, the European Alliance of Associations For Rheumatology, is Europe’s largest arthritis medical conference, served as the platform for CreakyJoints’ social media posts which received more ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in systemic lupus erythematosus, according to data presented at the EULAR 2025 ...

Source Reference: Eshak N, et al "Exploring GLP-1 agonists effects in fibromyalgia patients: A propensity matched analysis using TriNetX database" EULAR 2025; Abstract OP0281.

Connective tissue diseases articles from across Nature Portfolio Connective tissue diseases are a heterogeneous group of autoimmune disorders that affect any of the body's connective tissues ...

Objectives The aim of the study was to evaluate the ultrasound findings in lacrimal glands in a cohort of patients with suspected primary Sjögren’s disease (pSjD) and to assess the relationship with ...

In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the ...